Announcements

Director Craig Eagle of OS Therapies Inc filed a Form 4 on October 30, 2026, disclosing the grant of stock options to purchase 300,000 shares of common stock on October 22, 2026.

Director Olivier Roger Jarry filed a Form 4 with the SEC on October 30, 2026, disclosing the grant of stock options to purchase 300,000 shares of OS Therapies Inc common stock on October 22, 2026.

Belite Bio, Inc. Chief Executive Officer and Director Lin Yu-Hsin filed a statement of changes in beneficial ownership on October 30, 2026, reporting the vesting of 5,000 ordinary shares under a restricted stock unit award originally granted on September 15, 2025.

Hao-Yuan Chuang, Chief Financial Officer and Director of Belite Bio, Inc, filed a Form 4 on October 30, 2026, disclosing the vesting of 5,000 ordinary shares from a restricted stock unit award originally granted on September 15, 2025.

Director Theodore F. Search filed a Form 4 with the SEC on October 30, 2026, disclosing a stock option grant and reporting his current beneficial ownership of common stock in OS Therapies Inc (NYSE:OSTX).

OS Therapies Inc director John Ciccio filed a Form 4 on October 30, 2026, disclosing the grant of 300,000 stock options and reporting his current beneficial ownership of common stock.

OS Therapies Inc President and CEO Paul A. Romness filed a Form 4 on October 30, 2026, reporting the grant of 900,000 stock options on October 22, 2026, with an exercise price of $1.25 per share.